Creative Medical Technology Marks a Milestone with INN Approval
PHOENIX — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a pioneering clinical-stage biotechnology firm focused on regenerative medicine, has recently reached a significant milestone. The World Health Organization (WHO) has officially recognized "olastrocel" as the International Non-Proprietary Name (INN) for the active cellular substance in CELZ-201, their flagship allogeneic cell therapy also referred to as AlloStem®.
Understanding the Importance of INN
The INN serves as a universally accepted, unique identifier for therapeutic substances. This designation is crucial for regulators, clinicians, and researchers, providing clarity throughout the therapeutic product's lifecycle—from development to commercialization. Timothy Warbington, President and CEO of Creative Medical, emphasized that this approval marks an important development in their journey, asserting its significance for global adoption and scalability of their innovative therapies.
The Vision Behind Olastrocel
Warbington expressed that having a WHO-recognized INN strengthens Creative Medical's position and adds credibility to their therapeutic approach. He noted, "This unified identity is vital as we push forward with our clinical strategies targeting major health concerns including chronic lower back pain, diabetes, and immune-mediated diseases—all of which present enormous market opportunities."
Accelerating Development with FDA Designations
Creative Medical Technologies isn't stopping at the INN approval. The company is also actively pursuing its FDA Fast Track designation specifically for the treatment of degenerative disc disease. This dual recognition amplifies their presence in an arena demanding innovative solutions for long-standing conditions.
What Olastrocel (CELZ-201) is All About
Olastrocel represents an allogeneic cellular therapeutic candidate sourced from perinatal tissue, showcasing the cutting-edge advancements under the AlloStem® platform. It aims to provide effective treatment options for various medical conditions, including:
- Chronic lower back pain and degenerative disc disease (DDD)
- New-onset Type 1 diabetes
- Biodefense-related health issues
About Creative Medical Technology Holdings, Inc.
This innovative company is on a mission to tackle unmet medical needs through its extensive pipeline of cell and immune therapies, particularly in neurology, urology, orthopedics, and autoimmune diseases. Armed with proprietary regenerative platforms and a solid regulatory strategy, Creative Medical leverages scientific expertise to accelerate the development of breakthrough therapies.
Contact Information for Inquiries
For more details about their groundbreaking work and vision, Creative Medical Technology Holdings can be contacted at:
Email: IR@CreativeMedicalTechnology.com
Website: www.creativemedicaltechnology.com
Frequently Asked Questions
What is the significance of the INN approval for Creative Medical?
The INN approval signifies global recognition and harmonization for the therapeutic compound, facilitating its development and market entry.
What conditions does Olastrocel aim to treat?
Olastrocel is designed to treat chronic lower back pain, Type 1 diabetes, and biodefense-related conditions among other targeted therapies.
Why is the FDA Fast Track designation important?
The FDA Fast Track designation accelerates the development and review of therapies that address unmet medical needs in serious conditions, paving the way for quicker patient access.
How does Creative Medical Technology ensure regulatory compliance?
Creative Medical employs a robust regulatory strategy combined with scientific innovations to navigate the complexities of regulatory landscapes across different markets.
Where can I learn more about Creative Medical Technology's initiatives?
More information about their groundbreaking research and therapies can be found on their official website at www.creativemedicaltechnology.com.
